Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematopoietic malignancies achieving >50% complete response rates in numerous refractory/relapsed B cell malignancies. However, there are challenges that hinder CAR-T efficacy and bar the broader use of this therapy in patients. One approach to address these challenges is to create a safe allogeneic CAR cell product by using cells that do not cause graft versus host disease (GvHD). Invariant natural killer T (iNKT) cells are an ideal candidate as they are restricted to the monomorphic CD1d protein in contrast to HLA restricted αβ-T cells and therefore are safe in the allogeneic setting. Furthermore, iNKT cells possess inherent antitumor mechanisms including the expression of NK activating receptors and the capability to lyse M2 tumor associated macrophages via aberrant glycolipid presentation on CD1d. Previous work from our lab demonstrated iNKT cells derived from cord blood units (CB-iNKT) are enriched in naïve and central memory phenotype compared to iNKT cells derived from adult peripheral blood (AB-iNKT). Patients that receive CAR-T cells with higher proportions of naïve/central memory phenotype cells receive greater therapeutic benefit. Therefore, CB-CAR-iNKT cells may serve as an effective platform for allogeneic adoptive cell therapy. Here we evaluate the preclinical therapeutic potential of CB-CAR-iNKT cells by equipping them with 8F4CAR that is restricted to the acute myeloid leukemia (AML) associated antigen PR1 presented in the context of HLA/A2*01. We show CB-8F4CAR-iNKT cells expand in greater numbers compared to AB-8F4CAR-iNKT cells with equivalent 8F4CAR expression and iNKT cell purity. CB-8F4CAR-iNKT cells exhibit significantly higher CD62L expression indicating an enriched naïve and central memory phenotype compared to AB-8F4CAR-iNKT cells. While both CB-8F4CAR-iNKT cells and AB-8F4CAR-iNKT cells display potent AML cytotoxicity via 8F4CAR and iNKTCR in vitro, CB-8F4CAR-iNKT cells trend in an increase in proliferation after repeated leukemia challenge. The increased expression of CD62L and the increased proliferative potential of CB-8F4CAR-iNKT cells suggests an improvement in anti-leukemic activity over AB-8F4CAR-iNKT cells in vivo. We go on to show that CB-8F4CAR-iNKT cells are polarized to Th2 cytokine production after 8F4CAR mediated leukemia cytolysis, which is consistent with iNKTCR mediated stimulation of parental CB-iNKT cells. Importantly, CB-8F4CAR-iNKT cells display anti-leukemic activity in vivo. This thesis supports the idea that CB-iNKT cells can be an effective allogeneic CAR therapy and supports the use of CB-iNKT cells as a platform to target hematopoietic malignancies.
","abstract_html":"<p>Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematopoietic malignancies achieving >50% complete response rates in numerous refractory/relapsed B cell malignancies. However, there are challenges that hinder CAR-T efficacy and bar the broader use of this therapy in patients. One approach to address these challenges is to create a safe allogeneic CAR cell product by using cells that do not cause graft versus host disease (GvHD). Invariant natural killer T (iNKT) cells are an ideal candidate as they are restricted to the monomorphic CD1d protein in contrast to HLA restricted αβ-T cells and therefore are safe in the allogeneic setting. Furthermore, iNKT cells possess inherent antitumor mechanisms including the expression of NK activating receptors and the capability to lyse M2 tumor associated macrophages via aberrant glycolipid presentation on CD1d. Previous work from our lab demonstrated iNKT cells derived from cord blood units (CB-iNKT) are enriched in naïve and central memory phenotype compared to iNKT cells derived from adult peripheral blood (AB-iNKT). Patients that receive CAR-T cells with higher proportions of naïve/central memory phenotype cells receive greater therapeutic benefit. Therefore, CB-CAR-iNKT cells may serve as an effective platform for allogeneic adoptive cell therapy. Here we evaluate the preclinical therapeutic potential of CB-CAR-iNKT cells by equipping them with 8F4CAR that is restricted to the acute myeloid leukemia (AML) associated antigen PR1 presented in the context of HLA/A2*01. We show CB-8F4CAR-iNKT cells expand in greater numbers compared to AB-8F4CAR-iNKT cells with equivalent 8F4CAR expression and iNKT cell purity. CB-8F4CAR-iNKT cells exhibit significantly higher CD62L expression indicating an enriched naïve and central memory phenotype compared to AB-8F4CAR-iNKT cells. While both CB-8F4CAR-iNKT cells and AB-8F4CAR-iNKT cells display potent AML cytotoxicity via 8F4CAR and iNKTCR <em>in vitro</em>, CB-8F4CAR-iNKT cells trend in an increase in proliferation after repeated leukemia challenge. The increased expression of CD62L and the increased proliferative potential of CB-8F4CAR-iNKT cells suggests an improvement in anti-leukemic activity over AB-8F4CAR-iNKT cells <em>in vivo</em>. We go on to show that CB-8F4CAR-iNKT cells are polarized to Th2 cytokine production after 8F4CAR mediated leukemia cytolysis, which is consistent with iNKTCR mediated stimulation of parental CB-iNKT cells. Importantly, CB-8F4CAR-iNKT cells display anti-leukemic activity <em>in vivo</em>. This thesis supports the idea that CB-iNKT cells can be an effective allogeneic CAR therapy and supports the use of CB-iNKT cells as a platform to target hematopoietic malignancies.</p>","abstract_has_math":false,"creators":["Grefe, Maison","0000-0003-1423-6658
"],"institution":null,"degree_name":"Masters of Science (MS)","degree_level":"Thesis (MS)","degree_discipline":null,"degree_department":null,"school":null,"contributors":["Jin S. Im, MD, PhD","Jeffrey J. Molldrem, MD","Leonid S. Metelitsa, MD, PhD"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-05-01T07:00:00Z","date_published":"2024-05-01T07:00:00Z","updated_at":"2026-07-24T05:48:59Z","subjects":["natural killer T cell","iNKT","chimeric antigen receptor","CAR-iNKT","cord blood","acute myeloid leukemia","Medical Cell Biology","Medical Immunology","Neoplasms","Translational Medical Research"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1350","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Jin S. Im, MD, PhD","Jeffrey J. Molldrem, MD","Leonid S. Metelitsa, MD, PhD"]},{"key":"dc:creator","label":"Author","values":["Grefe, Maison","0000-0003-1423-6658
"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2024-04-25T07:00:00Z"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis (MS)"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Masters of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["natural killer T cell","iNKT","chimeric antigen receptor","CAR-iNKT","cord blood","acute myeloid leukemia","Medical Cell Biology","Medical Immunology","Neoplasms","Translational Medical Research"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1350"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematopoietic malignancies achieving >50% complete response rates in numerous refractory/relapsed B cell malignancies. However, there are challenges that hinder CAR-T efficacy and bar the broader use of this therapy in patients. One approach to address these challenges is to create a safe allogeneic CAR cell product by using cells that do not cause graft versus host disease (GvHD). Invariant natural killer T (iNKT) cells are an ideal candidate as they are restricted to the monomorphic CD1d protein in contrast to HLA restricted αβ-T cells and therefore are safe in the allogeneic setting. Furthermore, iNKT cells possess inherent antitumor mechanisms including the expression of NK activating receptors and the capability to lyse M2 tumor associated macrophages via aberrant glycolipid presentation on CD1d. Previous work from our lab demonstrated iNKT cells derived from cord blood units (CB-iNKT) are enriched in naïve and central memory phenotype compared to iNKT cells derived from adult peripheral blood (AB-iNKT). Patients that receive CAR-T cells with higher proportions of naïve/central memory phenotype cells receive greater therapeutic benefit. Therefore, CB-CAR-iNKT cells may serve as an effective platform for allogeneic adoptive cell therapy. Here we evaluate the preclinical therapeutic potential of CB-CAR-iNKT cells by equipping them with 8F4CAR that is restricted to the acute myeloid leukemia (AML) associated antigen PR1 presented in the context of HLA/A2*01. We show CB-8F4CAR-iNKT cells expand in greater numbers compared to AB-8F4CAR-iNKT cells with equivalent 8F4CAR expression and iNKT cell purity. CB-8F4CAR-iNKT cells exhibit significantly higher CD62L expression indicating an enriched naïve and central memory phenotype compared to AB-8F4CAR-iNKT cells. While both CB-8F4CAR-iNKT cells and AB-8F4CAR-iNKT cells display potent AML cytotoxicity via 8F4CAR and iNKTCR in vitro, CB-8F4CAR-iNKT cells trend in an increase in proliferation after repeated leukemia challenge. The increased expression of CD62L and the increased proliferative potential of CB-8F4CAR-iNKT cells suggests an improvement in anti-leukemic activity over AB-8F4CAR-iNKT cells in vivo. We go on to show that CB-8F4CAR-iNKT cells are polarized to Th2 cytokine production after 8F4CAR mediated leukemia cytolysis, which is consistent with iNKTCR mediated stimulation of parental CB-iNKT cells. Importantly, CB-8F4CAR-iNKT cells display anti-leukemic activity in vivo. This thesis supports the idea that CB-iNKT cells can be an effective allogeneic CAR therapy and supports the use of CB-iNKT cells as a platform to target hematopoietic malignancies.
"]},{"key":"dc:title","label":"Title","values":["Cord Blood-Derived Invariant Natural Killer T Cells as a Platform for Allogeneic Chimeric Antigen Receptor Cell Therapy"]}]}],"canonical_facts":{"dc:contributor":["Jin S. Im, MD, PhD","Jeffrey J. Molldrem, MD","Leonid S. Metelitsa, MD, PhD"],"dc:creator":["Grefe, Maison","0000-0003-1423-6658
"],"dc:date.available":["2024-04-25T07:00:00Z"],"dc:description.abstract":["Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematopoietic malignancies achieving >50% complete response rates in numerous refractory/relapsed B cell malignancies. However, there are challenges that hinder CAR-T efficacy and bar the broader use of this therapy in patients. One approach to address these challenges is to create a safe allogeneic CAR cell product by using cells that do not cause graft versus host disease (GvHD). Invariant natural killer T (iNKT) cells are an ideal candidate as they are restricted to the monomorphic CD1d protein in contrast to HLA restricted αβ-T cells and therefore are safe in the allogeneic setting. Furthermore, iNKT cells possess inherent antitumor mechanisms including the expression of NK activating receptors and the capability to lyse M2 tumor associated macrophages via aberrant glycolipid presentation on CD1d. Previous work from our lab demonstrated iNKT cells derived from cord blood units (CB-iNKT) are enriched in naïve and central memory phenotype compared to iNKT cells derived from adult peripheral blood (AB-iNKT). Patients that receive CAR-T cells with higher proportions of naïve/central memory phenotype cells receive greater therapeutic benefit. Therefore, CB-CAR-iNKT cells may serve as an effective platform for allogeneic adoptive cell therapy. Here we evaluate the preclinical therapeutic potential of CB-CAR-iNKT cells by equipping them with 8F4CAR that is restricted to the acute myeloid leukemia (AML) associated antigen PR1 presented in the context of HLA/A2*01. We show CB-8F4CAR-iNKT cells expand in greater numbers compared to AB-8F4CAR-iNKT cells with equivalent 8F4CAR expression and iNKT cell purity. CB-8F4CAR-iNKT cells exhibit significantly higher CD62L expression indicating an enriched naïve and central memory phenotype compared to AB-8F4CAR-iNKT cells. While both CB-8F4CAR-iNKT cells and AB-8F4CAR-iNKT cells display potent AML cytotoxicity via 8F4CAR and iNKTCR in vitro, CB-8F4CAR-iNKT cells trend in an increase in proliferation after repeated leukemia challenge. The increased expression of CD62L and the increased proliferative potential of CB-8F4CAR-iNKT cells suggests an improvement in anti-leukemic activity over AB-8F4CAR-iNKT cells in vivo. We go on to show that CB-8F4CAR-iNKT cells are polarized to Th2 cytokine production after 8F4CAR mediated leukemia cytolysis, which is consistent with iNKTCR mediated stimulation of parental CB-iNKT cells. Importantly, CB-8F4CAR-iNKT cells display anti-leukemic activity in vivo. This thesis supports the idea that CB-iNKT cells can be an effective allogeneic CAR therapy and supports the use of CB-iNKT cells as a platform to target hematopoietic malignancies.
"],"dc:identifier":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1350"],"dc:subject":["natural killer T cell","iNKT","chimeric antigen receptor","CAR-iNKT","cord blood","acute myeloid leukemia","Medical Cell Biology","Medical Immunology","Neoplasms","Translational Medical Research"],"dc:title":["Cord Blood-Derived Invariant Natural Killer T Cells as a Platform for Allogeneic Chimeric Antigen Receptor Cell Therapy"],"thesis:degree_level":["Thesis (MS)"],"thesis:degree_name":["Masters of Science (MS)"]},"updated_at":"2026-07-24T05:48:59Z"}